Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04795063 |
Recruitment Status :
Not yet recruiting
First Posted : March 12, 2021
Last Update Posted : March 12, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastric Cancer Robotic Gastrectomy | Procedure: Total Robotic Distal Gastrectomy Procedure: Robotic-Assisted Distal Gastrectomy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 160 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized Controlled Trials on Clinical Outcomes of Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer |
Estimated Study Start Date : | March 1, 2021 |
Estimated Primary Completion Date : | January 1, 2024 |
Estimated Study Completion Date : | January 1, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Total Robotic Distal Gastrectomy
After exploration and randomization, patients received total robotic distal gastrectomy
|
Procedure: Total Robotic Distal Gastrectomy
All the surgical procedures are performed using the robot system. |
Active Comparator: Robotic-Assisted Distal Gastrectomy
After exploration and randomization, patients received robotic-assisted distal gastrectomy.
|
Procedure: Robotic-Assisted Distal Gastrectomy
After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal. |
- Morbidity rates [ Time Frame: 30 days ]This is for the early postoperative complication, which defined as the event observed within 30 days after surgery.
- 3-year disease free survival rate [ Time Frame: 36 months ]3-year disease free survival rate
- 3-year overall survival rate [ Time Frame: 36 months ]3-year overall survival rate
- 3-year recurrence pattern [ Time Frame: 36 months ]Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.
- intraoperative morbidity rates [ Time Frame: 1 day ]The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.
- overall postoperative serious morbidity rates [ Time Frame: 30 days ]Refers to the incidence of early postoperative complication which is graded as Clavien-Dindo IIIA or higher
- Total Number of Retrieved Lymph Nodes [ Time Frame: 1 day ]Total Number of Retrieved Lymph Nodes
- postoperative recovery course [ Time Frame: 30 days ]Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.
- postoperative nutritional status [ Time Frame: 3, 6, 9 and 12 months ]The variation of weight on postoperative 3, 6, 9 and 12 months are used to access the postoperative nutritional status.
- inflammatory immune response [ Time Frame: Preoperative 3 days and postoperative 1, 3, and 5 days ]The variation of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response
- Time of digestive tract reconstruction [ Time Frame: 1 day ]From the beginning to the end of digestive tract reconstruction
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age from over 18 to under 75 years
- Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy
- cT1-4a (clinical stage tumor), N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
- expected to perform distal gastrectomy with D1+/D2 lymph node dissection to obtain R0 resection surgicall results.
- Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
- American Society of Anesthesiology (ASA) class I to III
- Written informed consent
Exclusion Criteria:
- Women during pregnancy or breast-feeding
- Severe mental disorder
- History of previous upper abdominal surgery (except laparoscopic cholecystectomy)
- History of previous gastric surgery (except Endoscopic Submucosal Dissection/Endoscopic Mucosal Resection (ESD/EMR) for gastric cancer)
- Gastric multiple primary carcinoma
- Enlarged or bulky regional lymph node (diameter over 3cm)supported by preoperative imaging
- History of other malignant disease within the past 5 years
- History of previous neoadjuvant chemotherapy or radiotherapy
- History of unstable angina or myocardial infarction within the past 6 months
- History of cerebrovascular accident within the past 6 months
- History of continuous systematic administration of corticosteroids within 1 month
- Requirement of simultaneous surgery for other disease
- Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
- Forced expiratory volume in 1 second (FEV1)<50% of the predicted values
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04795063
Contact: Chang-ming Huang, MD | +86-13805069676 | hcmlr2002@163.com | |
Contact: Qi-yue Chen, PhD | +86-15980235636 | 690934662@qq.com |
China, Fujian | |
Fujian Medical University Union Hospital | |
Fuzhou, Fujian, China, 350001 | |
Contact: Changming Huang, M.D., Ph.D. +86-133-6591-0253 hcmlr2002@163.com | |
Principal Investigator: Changming Huang, M.D., Ph.D. |
Study Chair: | Chang-ming Huang, MD | Fujian Medical University Union Hospital |
Responsible Party: | Chang-Ming Huang, Prof., Professor, Fujian Medical University |
ClinicalTrials.gov Identifier: | NCT04795063 |
Other Study ID Numbers: |
FUGES-022 |
First Posted: | March 12, 2021 Key Record Dates |
Last Update Posted: | March 12, 2021 |
Last Verified: | March 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Gastric Cancer robotic assisted distal gastrectomy total robotic distal gastrectomy |
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases |